Document is current

Article History

Accepted: 24 January 2023

First Online: 13 April 2023

Declarations

:

: No sources of funding were received for the preparation of this article.

: Adam Daunton has served as a paid speaker and advisor for Eli Lilly. Rodney Sinclair is on the Pharmaceutical Advisory Board for Eli Lilly and Company, Pfizer Inc. and Leo Pharmaceutical, is on the Speaker Bureau for Pfizer, AbbVie and Novartis, is a Principal Investigator in clinical trials for AbbVie, Aerotech, Akesobio, Amgen, Arcutis, Arena, Ascend, AstraZeneca, Bayer AG, Biotherapeutics, Boehringer Ingelheim, Bristol Myer Squibb, Celgene, Coherus BioSciences, Connect, Demira, Eli Lilly and Company, Galderma, Glaxo Smith Kline, F. Hoffman-La Roche, Janssen, MedImmune, Merck and Co, Merck Sharpe & Dohme, Novartis, Oncobiologics, Pfizer, Principia, Regeneron, Roche, Reistone Biopharma, Samson Clinical, Sanofi-Genzyme, Sun Pharma, UCB, and Valeant, and is serving as the current President of the Australasian Hair and Wool Research Society. Matthew Harries has been Principal Investigator in a clinical trial for Manentia; and paid advisor to Eli Lilly and Pfizer (fees paid to his Institution), Ralf Paus, Antonella Tosti, and Andrew Messenger have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: All available as per references.

: Data sharing is not applicable to this article as no new datasets were generated or analysed during the current study.

: AD and MH conceptualised and designed the methodology for this study. AD and MH undertook the systematic literature search and critical appraisal. AD prepared the original draft. AD, MH, RS, RP, AT and AM all contributed towards the critical review, commentary, and revision of the original manuscript.